Insulin glulisine
PDB: 6gv0 | |
| Clinical data | |
|---|---|
| Trade names | Apidra, Apidra Solostar |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607033 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous, intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C258H384N64O78S6 |
| Molar mass | 5822.64 g·mol−1 |
| (what is this?) (verify) | |
Insulin glulisine, sold under the brand name Apidra among others, is a rapid-acting modified form of medical insulin used for the treatment of diabetes. It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[2] When injected subcutaneously, it appears in the blood earlier than regular human insulin (RHI).[4] Intravenous injections may be used for extreme hyperglycemia.[2] It was developed by Sanofi-Aventis.
The most common side effects include hypoglycaemia (low blood glucose levels).[3]
Insulin glulisine was approved for medical use in the United States[2][5] and in the European Union[3] in 2004.
- ^ "Insulin glulisine Use During Pregnancy". Drugs.com. 6 April 2020. Retrieved 21 September 2020.
- ^ a b c d "Apidra- insulin glulisine injection, solution; Apidra Solostar- insulin glulisine injection, solution". DailyMed. 25 July 2023. Retrieved 10 August 2024.
- ^ a b c "Apidra EPAR". European Medicines Agency (EMA). 27 July 2009. Retrieved 7 October 2020.
- ^ Garnock-Jones KP, Plosker GL (May 2009). "Insulin glulisine: a review of its use in the management of diabetes mellitus". Drugs. 69 (8): 1035–57. doi:10.2165/00003495-200969080-00006. PMID 19496630. S2CID 41839395.
- ^ "Drug Approval Package: Apidra (Insulin Glulisine [rDNA Origin]) NDA #021629". U.S. Food and Drug Administration (FDA). Archived from the original on 5 April 2015. Retrieved 10 August 2024.